Ironwood Pharmaceuticals Shares Are Trading Lower After the Company's Phase 3 Trial of Once-weekly Subcutaneous Apraglutide Did Not Meet Two Out of Four Key Secondary Endpoints
Ironwood Pharmicals的股价走低,此前该公司每周一次的皮下阿普拉鲁肽的第三阶段试验未达到四个关键次要终点中的两个
Ironwood Pharmaceuticals Shares Are Trading Lower After the Company's Phase 3 Trial of Once-weekly Subcutaneous Apraglutide Did Not Meet Two Out of Four Key Secondary Endpoints
Ironwood Pharmicals的股价走低,此前该公司每周一次的皮下阿普拉鲁肽的第三阶段试验未达到四个关键次要终点中的两个
使用浏览器的分享功能,分享给你的好友吧